- Home
- BCAB vs TRIB Comparison
BCAB vs TRIB Comparison
Compare BCAB & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- TRIB
- Stock Information
- Founded
- BCAB 2007
- TRIB 1992
- Country
- BCAB United States
- TRIB Ireland
- Employees
- BCAB N/A
- TRIB N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCAB Health Care
- TRIB Health Care
- Exchange
- BCAB Nasdaq
- TRIB Nasdaq
- Market Cap
- BCAB 27.0M
- TRIB 25.5M
- IPO Year
- BCAB 2020
- TRIB N/A
- Fundamental
- Price
- BCAB $0.31
- TRIB $0.74
- Analyst Decision
- BCAB Buy
- TRIB
- Analyst Count
- BCAB 2
- TRIB 0
- Target Price
- BCAB $5.00
- TRIB N/A
- AVG Volume (30 Days)
- BCAB 1.1M
- TRIB 110.4K
- Earning Date
- BCAB 03-25-2025
- TRIB 04-03-2025
- Dividend Yield
- BCAB N/A
- TRIB N/A
- EPS Growth
- BCAB N/A
- TRIB N/A
- EPS
- BCAB N/A
- TRIB N/A
- Revenue
- BCAB $11,000,000.00
- TRIB $59,126,000.00
- Revenue This Year
- BCAB N/A
- TRIB $11.63
- Revenue Next Year
- BCAB N/A
- TRIB $10.13
- P/E Ratio
- BCAB N/A
- TRIB N/A
- Revenue Growth
- BCAB N/A
- TRIB N/A
- 52 Week Low
- BCAB $0.24
- TRIB $0.63
- 52 Week High
- BCAB $4.02
- TRIB $3.55
- Technical
- Relative Strength Index (RSI)
- BCAB 32.63
- TRIB 46.01
- Support Level
- BCAB $0.24
- TRIB $0.63
- Resistance Level
- BCAB $0.36
- TRIB $0.77
- Average True Range (ATR)
- BCAB 0.04
- TRIB 0.06
- MACD
- BCAB 0.01
- TRIB 0.00
- Stochastic Oscillator
- BCAB 29.39
- TRIB 46.91
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.